Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs

New England Journal of Medicine

Volumn 340, Issue 24, 1999, Pages 1888-1899

  Wolfe, M Michael ^a,c   Lichtenstein, David R ^a   Singh, Gurkirpal ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BILE SALT; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; FAMOTIDINE; FLURBIPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; LEUKOTRIENE; MISOPROSTOL; NITRIC OXIDE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PEPSIN A; PHOSPHOLIPASE A2; PHOSPHOLIPID; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR; SUCRALFATE; SULINDAC; SULINDAC SULFIDE; UNINDEXED DRUG;

CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DYSPEPSIA; GASTROINTESTINAL TOXICITY; GENE; HELICOBACTER PYLORI; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; ULCER HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DYSPEPSIA; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL MUCOSA; PEPTIC ULCER; PROSTAGLANDINS; RISK FACTORS; UNITED STATES;

EID: 0033577982     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199906173402407     Document Type: Review

References (113)

1. Wallace J. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000-16.
2. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990;21:Suppl:IV-12-IV-23.
3. Dreser H. Pharmacologisches über aspirin (acetylsalicyl-saüre). Pflugers Arch 1899;76:306-18.
4. Douthwaite AH, Lintott GAM. Gastroscopic observation of effect of aspirin and certain other substances on stomach. Lancet 1938,2:1222-5.
5. Sun DC, Roth SH, Mitchell CS, Englund DW. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis 1974;19:405-10.
6. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease: a report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 1974;290:1158-62.
7. Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979;91:517-20.
8. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-9.
9. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum 1995;38:5-18.
10. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
11. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
12. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999;26:Suppl26:18-24.
13. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-32.
14. Singh G, Ramey DR, Terry R, Khraishi M, Triadafilopoulos G. NSAID-related effects on the GI tract: an ever widening spectrum. Arthritis Rheum 1997;40:Suppl:S93. abstract.
15. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-38S.
16. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med 1996;101:Suppl 1A:25S-32S.
17. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995;90:206-10.
18. Greene JM, Winickoff RN. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis: a review and suggestions. Arch Intern Med 1992;152:1995-2002.
19. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
20. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
21. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8. [Erratum, Lancet 1994;343:1302.]
22. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72. [Erratum, Lancet 1994;343:1048.]
23. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995;30:438-44.
24. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
25. Hochain P, Berkelmans I, Czernichow P, et al. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol 1995;7:419-26.
26. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
27. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
28. Barkin J. The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Am J Med 1998;105:22S-27S.
29. Goggin PM, Collins DA Jazrawi RP, et al. Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 1993;34:1677-80.
30. Kim JG, Graham DY. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol 1994;89:203-7.
31. Thillainayagam AV, Tabaqchali S, Warrington SJ, Farthing MJ. Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs, and gastroduodenal disease: a prospective study in healthy volunteers. Dig Dis Sci 1994;39:1085-9.
32. Laine L, Cominelli F, Sloane R, Casini-Raggi V, Marin-Sorensen M, Weinstein WM. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind study. Aliment Pharmacol Ther 1995;9:127-35.
33. Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: response to omeprazole dual therapy. Gut 1996;39:22-6.
34. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
35. Hawkey CJ, Tulassay Z, Szczepañski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998;352:1016-21. [Erratum, Lancet 1998;352:1634.]
36. Singh G, Ramey DR, Triadafilopoulus G, Brown BW, Balise RR. GI SCORE: a simple self-assessment instrument to quantify the risk of serious NSAID-related GI complications in RA and OA. Arthritis Rheum 1998; 41:Suppl:S7S. abstract.
37. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989;86:449-58.
38. Whittle BJR. Mechanisms underlying gastric mucosal damage induced by indomethacin and bile salts, and the actions of prostaglandins. Br J Pharmacol 1977;60:455-60.
39. Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med 1988;319:1707-15.
40. Graham DY, Smith JL, Holmes GI, Davies RO. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther 1985;38:65-70.
41. Carson JL, Strom BL, Morse L, et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987; 147:1054-9.
42. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114: 307-19.
43. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;24:Suppl 49:6-8.
44. Lanza FL, Royer GL Jr, Nelson RS. Endoscopie evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980;303:136-8.
45. Malickal J, Elboim CM. Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly. Ann Pharmacother 1995;29:698-701.
46. Henry D, Dobson A, Turner C. Viriability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078-88.
47. Lee M, Cryer B, Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994;120:184-9.
48. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A 1992;89:3917-21.
49. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997;24:Suppl 49:15-9.
50. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci U S A 1988;85:1412-6. [Erratum, Proc Natl Acad Sci U S A 1988;85:5056.]
51. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992;89:7384-8.
52. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92.
53. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990;259:G462-G467.
54. Wallace JL, McKnight W, Miyasaka M, et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol 1993;265:G993-G998.
55. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995;109:1173-80.
56. Santucci L, Fiorucci S, Giansanti M, Brunori PM, Di Matteo FM, Morelli A. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut 1994;35:909-15.
57. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992;16:227-40.
58. 4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742-7.
59. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986;104:390-8.
60. Berkowitz JM, Rogenes PR, Sharp JT, Warner CW. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med 1987;147:2137-9.
61. Konturek SJ, Kwiecien N, Obtulowicz W, Kopp B, Oleksy J. Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man. Gut 1986;27:1450-6.
62. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med 1984;77:19-24.
63. Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN. A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis. Am J Gastroenterol 1992;87:996-1000.
64. Graham DY, Smith JL. Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 1988;83:1081-4.
65. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989;96:Suppl:647-55.
66. Langman MJS. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology 1989; 96:Suppl:640-6.
67. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-80.
68. Pounder R. Silent peptic ulceration: deadly silence or golden silence? Gastroenterology 1989;96:Suppl:626-31.
69. Bijlsma JW. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: an international multicentre collaborative study. Aliment Pharmacol Ther 1988;2:Suppl 1:85-95.
70. Lanza FL, Aspinall RL, Swabb EA, Davis RE, Rack MF, Rubin A. A double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolemetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988;95: 289-94.
71. Saunders JHB, Oliver RJ, Higson DL. Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J 1986;292:665-8.
72. Van Groenendael JHLM, Markusse HM, Dijkmans BAC, Breedveld FC. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1996;15:450-6.
73. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-9.
74. Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719-26.
75. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.
76. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998,93:2037-46.
77. McCarthy DM. Sucralfate. N Engl J Med 1991;325:1017-25.
78. Croker JR, Cotton PB, Boyle AC, Kinsella P. Cimetidine for peptic ulcer in patients with arthritis. Ann Rheum Dis 1980;39:275-8.
79. Davies J, Collins AJ, Dixon SAJ. The influence of cimetidine on peptic ulcer in patients with arthritis taking anti-inflammatory drugs. Br J Rheumatol 1986;25:54-8.
80. O'Laughlin JC, Silvoso GK, Ivey KJ. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin: a double-blind study with cimetidine and follow-up. Dig Dis Sci 1982;27:976-80.
81. Walan A, Bader J-P, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69-75.
82. Agrawal N, Safdi M, Wruble L, Karvois D, Greski-Rose P, Huang B. Effectiveness of lansoprazole in the healing of NSAID-induced gastric ulcer in patients continuing to take NSAIDs. Gastroenterology 1998;114: A52-A53. abstract.
83. Caldwell JR, Roth SH, Wu WC, et al. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med 1987;83:Suppl 3B:74-82.
84. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991;115:195-200.
85. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34:424-8.
86. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastrointestinal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
87. Oddsson E, Gudjonsson H, Thjodleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol 1992;27:1045-8.
88. Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994;39:97-103.
89. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-62.
90. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123:344-50.
91. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-71.
92. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990;10:56-65.
93. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35:Suppl 1:68-77.
94. Wolfe MM. Future trends in the development of safer nonsteroidal anti-inflammatory drugs. Am J Med 1998;105:Suppl SA:44S-52S.
95. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol 1996;25:Suppl 102:9-21.
96. Vane JR, Botting RM. Overview: the mechanism of action of anti-inflammatory drugs. In: Vane JR, Botting R, eds. Clinical significance and potential of selective Cox-2 inhibitors. London: William Harvey Press, 1998:1-18.
97. Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 1997;32:126-30.
98. Lipsky PE, Isakson PC. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 1997;24:Suppl 49:9-14.
99. Lanza FL, Rack MF, Callison DA, et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor. Gastroenterology 1997;112:Suppl:A194. abstract.
100. Lanza F, Simon T, Quan H, et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.I.D. or ibuprofen (IBU) 800 mg T.I.D. Gastroenterology 1997;112:Suppl:A194. abstract.
101. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-stcroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
102. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-97.
103. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cydooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
104. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107: 1183-8.
105. Kitagawa H, Takeda F, Kohei H. Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCl in rats. J Pharmacol Exp Ther 1990;253:1133-7.
106. Kiraly A, Suto G, Taché Y. Role of nitric oxide in the gastric cytoprotection induced by central vagal stimulation. Eur J Pharmacol 1993; 240:299-301.
107. Masuda E, Kawano S, Nagano K, et al. Endogenous nitric oxide modulates ethanol-induced gastric mucosal injury in rats. Gastroenterology 1995;108:58-64.
108. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A 1993;90:7240-4.
109. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994;107:173-9.
110. Davies NM, Røseth AG, Appleyard CB, et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 1997;11:69-79.
111. Saha JK, Schroeder JD, Chen L, et al. Nitrosothiol based SNO-NSAIDs as novel anti-inflammatory, analgesic drugs with reduced gastrointestinal toxicity. Gastroenterology 1998;114:A274. abstract.
112. Donnelly MT, Stack WA, Courtauld EM, Garlick N, Del Soldato P, Hawkey CJ. Nitric oxide donating flurbiprofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen. Gastroenterology 1998;114:A107. abstract.
113. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995;96:2711-8.